Article

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancer

2019-06-24

Abstract excerpt

<h4>Background</h4> Prostate cancers with mutations in genes involved in homologous recombination (HR), most commonly BRCA2, respond favorably to PARP inhibition and platinum-based chemotherapy. It is not clear, however, whether other prostate tumors that do not harbor deleterious mutations in these particular genes can similarly be deficient in HR, rendering them sensitive to HR-directed therapies. To identify a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3b0bde59-2f8b-59dd-8cf6-2af1648886e8
DOI: 10.1101/681114

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerDOI 10.1101/681114Read

Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.Semantic proximity Read

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate CarcinomasSemantic proximity Read

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read

Clinical implications of homologous recombination repair mutations in prostate cancer.Semantic proximity Read

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read

Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitorsSemantic proximity Read

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair AlterationsSemantic proximity Read

Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic OpportunitiesSemantic proximity Read

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read